Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Skin sterol study

This article was originally published in The Tan Sheet

Executive Summary

People with high levels of skin tissue cholesterol and C-reactive protein have nearly double the risk of metabolic syndrome compared to those without elevated levels of both markers, according to data presented by PreMD at the American Heart Association's Annual Arteriosclerosis, Thrombosis & Vascular Biology conference in Toronto April 27. The study used PREVU* Point Of Care Skin Sterol Test to measure skin sterol and C-reactive protein levels in 301 patients with established coronary artery disease to assess whether the two markers could help predict metabolic syndrome. "The prevalence of metabolic syndrome in was significantly higher in patients who scored highest for both skin sterol and C-reactive protein, and remained significant after adjustment for age and gender, compared to isolated elevators of either marker alone," Milan Gupta, MD, McMaster University, Ontario, et al., state. PreMD is currently investigating a home-use version of the PREVU* test, which is currently designed for use by medical professionals. However, the home-use product has not yet entered the clinical stage, a spokesperson says...

You may also be interested in...

UK IVDs Firms Working Flat Out On COVID-19 Tests, As Govt Promises Test Capacity Increase

Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts